Activity of PD-1 inhibitor combined with anti-angiogenic therapy in advanced sarcoma: a single-center retrospective analysis
Y You, X Guo, R Zhuang, C Zhang, Z Wang… - Frontiers in Molecular …, 2021 - frontiersin.org
Background: Immune checkpoint inhibitors (ICIs) are employed to treat various cancers,
including soft tissue sarcomas (STSs), and less than 20% of patients benefit from this …
including soft tissue sarcomas (STSs), and less than 20% of patients benefit from this …
Molecular Heterogeneity in Leiomyosarcoma and Implications for Personalised Medicine
Leiomyosarcoma (LMS) is one of the most common soft tissue sarcoma (STS) subtypes,
accounting for 10–20% of cases [1]. The disease arises from the smooth muscle cell lineage …
accounting for 10–20% of cases [1]. The disease arises from the smooth muscle cell lineage …
[HTML][HTML] Two-step consensus clustering approach to immune cell infiltration: An integrated exploration and validation of prognostic and immune implications in …
AY Li, J Bu, HN Xiao, ZY Zhao, JL Zhang, B Yu, H Li… - Heliyon, 2024 - cell.com
To conduct a comprehensive investigation of the sarcoma immune cell infiltration (ImmCI)
patterns and tumoral microenvironment (TME). We utilized transcriptomic, clinical, and …
patterns and tumoral microenvironment (TME). We utilized transcriptomic, clinical, and …
[HTML][HTML] Gene expression-based prediction of pazopanib efficacy in sarcoma
CE Heilig, A Laßmann, SS Mughal, A Mock… - European Journal of …, 2022 - Elsevier
Background The multi-receptor tyrosine kinase inhibitor pazopanib is approved for the
treatment of advanced soft-tissue sarcoma and has also shown activity in other sarcoma …
treatment of advanced soft-tissue sarcoma and has also shown activity in other sarcoma …
Characterization of the immune cell infiltration landscape in myxofibrosarcoma to aid immunotherapy
ZY Zhao, ZY Chen, B Yu, B Xiao, LY Liu, Y Xia… - Frontiers in …, 2022 - frontiersin.org
Myxofibrosarcoma (MFS) is a highly malignant subtype of soft tissue sarcoma, accounting for
5% of cases. Immunotherapy guided by immune cell infiltration (ICI) is reportedly a …
5% of cases. Immunotherapy guided by immune cell infiltration (ICI) is reportedly a …
Response rates of pazopanib therapy in metastatic soft tissue sarcoma using real‑world data
CM Söylemez, P Gürsoy, UA Şanli - Oncology Letters, 2024 - spandidos-publications.com
The present study was a retrospective single-center study. A total of 81 patients diagnosed
with metastatic soft tissue sarcoma were included who received pazopanib therapy. Clinical …
with metastatic soft tissue sarcoma were included who received pazopanib therapy. Clinical …
PD-L1 expression in anaplastic thyroid carcinoma treated with lenvatinib
H Yamazaki, Y Okubo, T Yokose, H Iwasaki, T Sasada… - 2023 - researchsquare.com
Purpose This study aimed to estimate the proportion of patients with anaplastic thyroid
carcinoma (ATC) at our institution who are likely to have the efficacy of immune checkpoint …
carcinoma (ATC) at our institution who are likely to have the efficacy of immune checkpoint …